GlobeStar Therapeutics Corporation announced earnings results for the third quarter ended June 30, 2021. For the third quarter, the company announced operating loss was USD 4.478 million compared to USD 48,563 a year ago. Net loss was USD 4.518 million compared to USD 87,985 a year ago. Basic loss per share from continuing operations was USD 0.01. For the nine months, operating loss was USD 5.008 million compared to USD 174,185 a year ago. Net loss was USD 5.538 million compared to USD 367,334 a year ago. Basic loss per share from continuing operations was USD 0.01.